VYMI - Vanguard Intl Hi Div Yld Idx ETF

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
59.43
+0.53 (+0.90%)
As of 12:56PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close58.90
Open59.33
Bid59.40 x 800
Ask59.43 x 2200
Day's Range59.23 - 59.46
52 Week Range54.41 - 72.32
Volume40,536
Avg. Volume181,195
Net Assets1.06B
NAV56.26
PE Ratio (TTM)N/A
Yield4.29%
YTD Return-12.66%
Beta (3Y Monthly)0.00
Expense Ratio (net)0.32%
Inception Date2016-02-26
Trade prices are not sourced from all markets
  • Business Wire7 months ago

    E*TRADE Adds Several of Today’s Most Popular ETFs to Commission-Free ETF Lineup

    E*TRADE Financial Corporation today announced it has surpassed 250 commission-free ETFs with the addition of 46 ETFs from six providers to its Commission-Free ETF Pr

  • Morningstar8 months ago

    How Much Foreign Currency Exposure Do Retirees Need?

    Retirees are often on the hunt for income, and foreign stocks and bonds tantalize by offering yields that are often higher than comparable payouts available on the home front. Foreign bonds from developed markets yield less than U.S. bonds today, but emerging-markets bonds, especially those denominated in local currencies, offer positively robust yields of 5% or 6%. When foreign currencies gain in value relative to the dollar, investors who own foreign-currency-denominated stocks and bonds win.

  • InvestorPlace9 months ago

    7 Vanguard ETFs for Buy-and-Hold Investors

    Compared to rivals such as iShares and State Street’s SPDR brand, Vanguard’s lineup of exchange-traded funds (ETFs) is small.

  • ETF Trends9 months ago

    A Globe-Trotting Dividend Idea As US Rates Rise

    At a time when U.S. interest rates are rising, income investors may want to consider ex-US dividend stocks and the related exchange traded funds. One idea on that front is the Vanguard International High ...

  • Morningstar9 months ago

    A Tale of Two High-Dividend-Yield ETFs

    A good process helps mitigate risk.

  • Benzinga11 months ago

    A Nifty Idea For International Dividends

    Markets outside the United States, both developed and emerging, offer income investors compelling opportunities to find dividend growth and higher yields than equivalent U.S. stocks. Exchange-traded funds ...

  • ETF Trends11 months ago

    An Interesting International Income ETF

    Ex-U.S. developed market dividend payers often feature larger yields than their U.S. counterparts, an assertion proven by comparing large- and mega-cap dividend stocks from familiar dividend sectors such ...

  • GlaxoSmithKline Is Global Leader in Consumer Healthcare Business
    Market Realist11 months ago

    GlaxoSmithKline Is Global Leader in Consumer Healthcare Business

    In 3Q17, GlaxoSmithKline (GSK) reported revenues close to 2.0 billion pounds from the sale of its consumer healthcare products, which is year-over-year (or YoY) growth of 5% on a reported basis and 2% on a constant exchange rate (or CER). GlaxoSmithKline witnessed sales worth 429 million pounds for its consumer healthcare franchise in the US market in 3Q17, which is YoY growth of 1% on a reported basis but a drop of 1% on a CER basis.

  • Morningstar11 months ago

    A Better Approach to High-Yielding Foreign Stocks

    This value fund targets high-yield stocks and emphasizes large, stable firms.

  • Nucala May Be a Game-Changing Product in Respiratory Segment
    Market Realistlast year

    Nucala May Be a Game-Changing Product in Respiratory Segment

    On November 4, 2015, the U.S. Food and Drug Administration (or FDA) approved GlaxoSmithKline’s (GSK) interleukin-5 antagonist monoclonal antibody, Nucala, as maintenance therapy for severe eosinophilic asthma patients who have been previously treated with other asthma medications and are 12 years or older. On December 12, 2017, the FDA expanded Nucala’s label and approved the therapy for patients suffering from eosinophilic granulomatosis with polyangiitis (or EGPA).

  • This Could Significantly Drive Gilead’s Revenue Growth in 2018
    Market Realistlast year

    This Could Significantly Drive Gilead’s Revenue Growth in 2018

    Where's Gilead Sciences Now? Key January UpdatesRecent developments for GILD

  • Will ZBH Beat Wall Street Earnings Estimates in 4Q17?
    Market Realistlast year

    Will ZBH Beat Wall Street Earnings Estimates in 4Q17?

    What to Expect from ZBH's 4Q17 Earnings Results